# CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2015

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2015-05-01
- Accepted by EDGAR: May 1, 2015, 16:34 ET
- Period: 2015-03-31
- Accession: 0000064803-15-000023
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000006480315000023/cvs20150331-10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000006480315000023/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-01-01 to 2015-03-31 | $36.33bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-01-01 to 2015-03-31 | $30.17bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2015-01-01 to 2015-03-31 | $6.16bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2015-01-01 to 2015-03-31 | $2.13bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-01-01 to 2015-03-31 | $137.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-01-01 to 2015-03-31 | $777.0m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2015-01-01 to 2015-03-31 | $1.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-01-01 to 2015-03-31 | $1.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-01-01 to 2015-03-31 | 1,136,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2015-01-01 to 2015-03-31 | $1.98bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2015-01-01 to 2015-03-31 | $419.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2015-01-01 to 2015-03-31 | $399.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months, 2015-01-01 to 2015-03-31 | $2.01bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2015-03-31 | $1.52bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-03-31 | $25.62bn | us-gaap:AssetsCurrent |
| Total assets | at 2015-03-31 | $73.93bn | us-gaap:Assets |
| Current liabilities | at 2015-03-31 | $19.71bn | us-gaap:LiabilitiesCurrent |
| Short-term borrowings | at 2015-03-31 | $500.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2015-03-31 | $36.99bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 991 characters.

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended March 31, 2015, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2014 and 2013 Repurchase Programs. See Note 3 to the condensed consolidated financial statements.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| January 1, 2015 through January 31, 2015 | 16,795,255 | $94.49 | 16,795,255 | $10,684,839,660 |
| February 1, 2015 through February 28, 2015 | — | $— | — | $10,684,839,660 |
| March 1, 2015 through March 31, 2015 | — | $— | — | $10,684,839,660 |
| Totals | 16,795,255 |  | 16,795,255 |  |

31

## Market risk

As filed, 337 characters.

As of March 31, 2015, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes that as of March 31, 2015 its exposure to interest rate risk (inherent in the Company’s debt portfolio), foreign currency exchange rate risk and commodity price risk is not material.

## Controls and procedures

As filed, 1,482 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of March 31, 2015, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** During the three months ended March 31, 2015, we implemented a new perpetual inventory system to account for front store inventories in our Retail Pharmacy Segment and changed our methods of accounting for front store inventories in the Retail Pharmacy Segment from the retail inventory method in retail stores and from the FIFO cost method in distribution centers to the weighted average cost method. Other than the foregoing, there have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended March 31, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed May 1, 2015.
Source: SEC EDGAR, the filing index for accession 0000064803-15-000023. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
